Skip to main content
Have a personal or library account? Click to login
Magnetic nanoparticles as targeted delivery systems in oncology Cover

Magnetic nanoparticles as targeted delivery systems in oncology

By:  and    
Open Access
|Jan 2011

References

  1. Widder KJ, Senyei AE, Ranney DF. Magnetically responsive microspheres and other carriers for the biophysical targeting of antitumor agents.1979;213-71.
  2. Scherer F, Anton M, Schillinger U, Henke J, Bergemann C, Krüger A, et al. Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo.2002;102-9.
  3. Morana G, Salviato E, Guarise A. Contrast agents for hepatic MRI.2007;S24-7.
  4. Kreuter J. Drug targeting with nanoparticles.1994;253-6.
  5. Filipponi L, Sutherland D, editors. Nanotechnology: a brief introduction [Internet]. Aarhus: University of Aarhus; 2007 [cited 2010 March 11]. Available from: http://www.nanocap.eu.
  6. Hunter R. Electrokinetics and the zeta potential. In: Hunter R, editor.New York: Oxford University Press; 2001. p. 373-434.
  7. Auffan M, Rose J, Bottero JY, Lowry GV, Jolivet JP, Wiesner MR. Towards a definition of inorganic nanoparticles from an environmental, health and safety perspective.2009;634-41.
  8. Gubin S. Introduction. In: Gubin S, editor.Weinheim: Wiley-VCH; 2009. p. 1-24.
  9. Bondi JF, Oyler KD, Ke X, Schiffer P, Schaak RE. Chemical synthesis of air-stable manganese nanoparticles.2009;9144-5.
  10. Alexiou C, Jurgons R. Magnetic drug targeting. In: Andrä W, Nowak H, editors.Berlin: Wiley-VCH; 2007. p. 596-605.
  11. Lowery T. Nanomaterials-based magnetic sensors switch biosensors. In: Kumar C, editor.Weinheim: Wiley-VCH; 2009. p. 3-54.
  12. Wilhelm C, Cebers A, Bacri JC, Gazeau F. Deformation of intracellular endosomes under a magnetic field.2003;655-60.
  13. Kirschvink JL, Kobayashi-Kirschvink A, Woodford BJ. Magnetite biomineralization in the human brain.1992;7683-7.
  14. Schultheiss-Grassi PP, Wessiken R, Dobson J. TEM investigations of biogenic magnetite extracted from the human hippocampus.1999;212-6.
  15. Soenen SJ, De Cuyper M. Assessing cytotoxicity of (iron oxide-based) nanoparticles: an overview of different methods exemplified with cationic magnetoliposomes.2009;207-19.
  16. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications.2005;3995-4021.
  17. Phenrat T, Saleh N, Sirk K, Tilton RD, Lowry GV. Aggregation and sedimentation of aqueous nanoscale zerovalent iron dispersions.2007;284-90.
  18. Prijic S, Scancar J, Romih R, Cemazar M, Bregar VB, Znidarsic A, et al. Increased cellular uptake of biocompatible superparamagnetic iron oxide nanoparticles into malignant cells by an external magnetic field.2010;167-79.
  19. Chertok B, David AE, Yang VC. Polyethyleneimine-modified iron oxide nanoparticles for brain tumor drug delivery using magnetic targeting and intra-carotid administration.2010;6317-24.
  20. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.1986;6387-92.
  21. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics.2008;1615-26.
  22. Leuschner C, Kumar CS, Hansel W, Soboyejo W, Zhou J, Hormes J. LHRH-conjugated magnetic iron oxide nanoparticles for detection of breast cancer metastases.2006;163-76.
  23. Babincova M, Babinec P. Magnetic drug delivery and targeting: principles and applications.2009;243-50.
  24. Mosso JA, Rand RW. Ferromagnetic silicone vascular occlusion: a technic for selective infarction of tumors and organs.1973;663-8.
  25. Lübbe AS, Bergemann C, Huhnt W, Fricke T, Riess H, Brock JW, et al. Preclinical experiences with magnetic drug targeting: tolerance and efficacy.1996;4694-701.
  26. Kumar A, Jena PK, Behera S, Lockey RF, Mohapatra S. Multifunctional magnetic nanoparticles for targeted delivery.2010;64-9.
  27. Chouly C, Pouliquen D, Lucet I, Jeune JJ, Jallet P. Development of superparamagnetic nanoparticles for MRI: effect of particle size, charge and surface nature on biodistribution.1996;245-55.
  28. Mykhaylyk O, Zelphati O, Hammerschmid E, Anton M, Rosenecker J, Plank C. Recent advances in magnetofection and its potential to deliver siRNAs in vitro.2009;111-46.
  29. Luo D, Saltzman WM. Enhancement of transfection by physical concentration of DNA at the cell surface.2000;893-5.
  30. Plank C, Schillinger U, Scherer F, Bergemann C, Rémy JS, Krötz F, et al. The magnetofection method: using magnetic force to enhance gene delivery.2003;737-47.
  31. Huth S, Lausier J, Gersting SW, Rudolph C, Plank C, Welsch U, et al. Insights into the mechanism of magnetofection using PEI-based magnetofectins for gene transfer.2004;923-36.
  32. Plank C, Scherer F, Schillinger U, Bergemann C, Anton M. Magnetofection: enhancing and targeting gene delivery with superparamagnetic nanoparticles and magnetic fields.2003;29-32.
  33. Gao H, Shi W, Freund LB. Mechanics of receptor-mediated endocytosis.2005;9469-74.
  34. Kim JS, Yoon TJ, Yu KN, Noh MS, Woo M, Kim BG, et al. Cellular uptake of magnetic nanoparticle is mediated through energy-dependent endocytosis in A549 cells.2006;321-6.
  35. Ma YJ, Gu HC. Study on the endocytosis and the internalization mechanism of aminosilane-coated Fe3O4 nanoparticles in vitro.2007;2145-9.
  36. Petri-Fink A, Chastellain M, Juillerat-Jeanneret L, Ferrari A, Hofmann H. Development of functionalized superparamagnetic iron oxide nanoparticles for interaction with human cancer cells.2005;2685-94.
  37. Prabha S, Zhou WZ, Panyam J, Labhasetwar V. Size-dependency of nanoparticle-mediated gene transfection: studies with fractionated nanoparticles.2002;105-15.
  38. Zauner W, Farrow NA, Haines AM. In vitro uptake of polystyrene microspheres: effect of particle size, cell line and cell density.2001;39-51.
  39. Jordan A, Scholz R, Wust P, Schirra K, Schiestel T, Schmidt H, et al. Endocytosis of dextran and silan-coated magnetite nanoparticles and the effect of intracellular hyperthermia on human mammary carcinoma cells in vitro.1999;185-96.
  40. Wilhelm C, Billotey C, Roger J, Pons JN, Bacri JC, Gazeau F. Intracellular uptake of anionic superparamagnetic nanoparticles as a function of their surface coating.2003;1001-11.
  41. Sincai M, Ganga D, Ganga M, Argherie D, Bica D. Antitumor effect of magnetite nanoparticles in cat mammary adenocarcinoma.2005;438-41.
  42. Mykhaylyk O, Antequera YS, Vlaskou D, Plank C. Generation of magnetic nonviral gene transfer agents and magnetofection in vitro.2007;2391-411.
  43. Wei W, Xu C, Wu H. Use of PEI-coated magnetic iron oxide nanoparticles as gene vectors.2004;618-20.
  44. Chen CB, Chen JY, Lee WC. Fast transfection of mammalian cells using superparamagnetic nanoparticles under strong magnetic field.2009;2651-9.
  45. Godbey WT, Wu KK, Mikos AG. Tracking the intracellular path of poly(ethylenimine)/DNA complexes for gene delivery.1999;5177-81.
  46. Florea BI, Meaney C, Junginger HE, Borchard G. Transfection efficiency and toxicity of polyethylenimine in differentiated Calu-3 and nondifferentiated COS-1 cell cultures.2002;E12.
  47. Smith CA, de la Fuente J, Pelaz B, Furlani EP, Mullin M, Berry CC. The effect of static magnetic fields and tat peptides on cellular and nuclear uptake of magnetic nanoparticles.2010;4392-400.
  48. Song HP, Yang JY, Lo SL, Wang Y, Fan WM, Tang XS, et al. Gene transfer using self-assembled ternary complexes of cationic magnetic nanoparticles, plasmid DNA and cell-penetrating Tat peptide.2010;769-78.
  49. Murata M, Takahashi S, Kagiwada S, Suzuki A, Ohnishi S. pH-dependent membrane fusion and vesiculation of phospholipid large unilamellar vesicles induced by amphiphilic anionic and cationic peptides.1992;1986-92.
  50. Plank C, Zatloukal K, Cotten M, Mechtler K, Wagner E. Gene transfer into hepatocytes using asialoglycoprotein receptor mediated endocytosis of DNA complexed with an artificial tetra-antennary galactose ligand.1992;533-9.
  51. Green M, Loewenstein PM. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein.1988;1179-88.
  52. Frankel AD, Bredt DS, Pabo CO. Tat protein from human immunodeficiency virus forms a metal-linked dimer.1988;70-3.
  53. Xylourgidis N, Fornerod M. Acting out of character: regulatory roles of nuclear pore complex proteins.2009;617-25.
  54. Xu C, Xie J, Kohler N, Walsh EG, Chin YE, Sun S. Monodisperse magnetite nanoparticles coupled with nuclear localization signal peptide for cell-nucleus targeting.2008;548-52.
  55. Müller RH, Maassen S, Weyhers H, Mehnert W. Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407.1996;161-70.
  56. Storm G, Belliot SO, Daemen T, Lasic DD. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system.1995;31-48.
  57. Jain TK, Reddy MK, Morales MA, Leslie-Pelecky DL, Labhasetwar V. Biodistribution, clearance, and biocompatibility of iron oxide magnetic nanoparticles in rats.2008;316-27.
  58. Mykhaylyk O, Cherchenko A, Ilkin A, Dudchenko N, Ruditsa V, Novoseletz M, et al. Glial brain tumor targeting of magnetite nanoparticles in rats.2001;241-47.
  59. Kim JS, Yoon TJ, Yu KN, Kim BG, Park SJ, Kim HW, et al. Toxicity and tissue distribution of magnetic nanoparticles in mice.2006;338-47.
  60. Lacava ZGM, Azevedo RB, Lacava LM, Martins EV, Garcia VAP, Rébula CA, et al. Toxic effects of ionic magnetic fluids in mice.1999;90-95.
  61. Lacava LM, Garcia VAP, Kückelhaus S, Azevedo RB, Sadeghiani N, Buske N, et al. Long-term retention of dextran-coated magnetite nanoparticles in the liver and spleen.2004;2434-35.
  62. Olden K, editor. Health effects from exposure to power-line frequency electric and magnetic fields [Internet]. Research triangle park (NC): National institute of environmental health sciences (US); 1999 [cited 2010 April 15]. Available from:
  63. Leszczynski D. Rapporteur report: cellular, animal and epidemiological studies of the effects of static magnetic fields relevant to human health.2005;247-53.
  64. Saunders R. Static magnetic fields: animal studies.2005;225-39.
  65. Sato K, Yamaguchi H, Miyamoto H, Kinouchi Y. Growth of human cultured cells exposed to a non-homogeneous static magnetic field generated by Sm-Co magnets.1992;231-8.
  66. Nakahara T, Yaguchi H, Yoshida M, Miyakoshi J. Effects of exposure of CHO-K1 cells to a 10-T static magnetic field.2002;817-22.
  67. Coletti D, Teodori L, Albertini MC, Rocchi M, Pristerà A, Fini M, et al. Static magnetic fields enhance skeletal muscle differentiation in vitro by improving myoblast alignment.2007;846-56.
  68. Kotani H, Kawaguchi H, Shimoaka T, Iwasaka M, Ueno S, Ozawa H, et al. Strong static magnetic field stimulates bone formation to a definite orientation in vitro and in vivo.2002;1814-21.
  69. Sun C, Lee JS, Zhang M. Magnetic nanoparticles in MR imaging and drug delivery.2008;1252-65.
  70. Saini S, Stark DD, Hahn PF, Wittenberg J, Brady TJ, Ferrucci JT. Ferrite particles: a superparamagnetic MR contrast agent for the reticuloendothelial system.1987;211-6.
  71. Saini S, Stark DD, Hahn PF, Bousquet JC, Introcasso J, Wittenberg J, et al. Ferrite particles: a superparamagnetic MR contrast agent for enhanced detection of liver carcinoma.1987;217-22.
  72. Weissleder R, Stark DD. Magnetic resonance imaging of liver tumors.1989;63-77.
  73. Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bengele HH, Josephson L. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging.1990;489-93.
  74. Chertok B, David AE, Moffat BA, Yang VC. Substantiating in vivo magnetic brain tumor targeting of cationic iron oxide nanocarriers via adsorptive surface masking.2009;6780-7.
  75. Chertok B, David AE, Huang Y, Yang VC. Glioma selectivity of magnetically targeted nanoparticles: a role of abnormal tumor hydrodynamics.2007;315-23.
  76. ClinicalTrials.gov [Internet]. Bethesda (MD): National Institutes of Health (US); 1993 - . Pre-operative staging of pancreatic cancer using superparamagnetic iron oxide magnetic resonance imaging (SPIO MRI) [cited 2010 September 12].; [about 3 p.]. Available from:
  77. Jain R, Dandekar P, Patravale V. Diagnostic nanocarriers for sentinel lymph node imaging.2009;90-102.
  78. Zhu L, Loo WT, Chow LW. Circulating tumor cells in patients with breast cancer: possible predictor of micro-metastasis in bone marrow but not in sentinel lymph nodes.2005;S355-8.
  79. Cammareri P, Lombardo Y, Francipane MG, Bonventre S, Todaro M, Stassi G. Isolation and culture of colon cancer stem cells.2008;311-24.
  80. Joo KM, Nam DH. Prospective identification of cancer stem cells with the surface antigen CD133.2009;57-71.
  81. Wang GY, Li Y, Yu YM, Yu B, Zhang ZY, Liu Y, et al. Detection of disseminated tumor cells in bone marrow of gastric cancer using magnetic activated cell sorting and fluorescent activated cell sorting.2009;299-306.
  82. Multhoff G, Botzler C, Wiesnet M, Müller E, Meier T, Wilmanns W, et al. A stress-inducible 72-kDa heat-shock protein (HSP72) is expressed on the surface of human tumor cells, but not on normal cells.1995;272-9.
  83. Johannsen M, Gneveckow U, Eckelt L, Feussner A, Waldöfner N, Scholz R, et al. Clinical hyperthermia of prostate cancer using magnetic nanoparticles: presentation of a new interstitial technique.2005;637-47.
  84. Maier-Hauff K, Rothe R, Scholz R, Gneveckow U, Wust P, Thiesen B, et al. Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: results of a feasibility study on patients with glioblastoma multiforme.2007;53-60.
  85. FDA-Approved Drugs [Internet]. Boston (MA): CenterWatch. 1995 - . FDA Approved Drugs for Oncology [cited 2010 September 14]; [about 7 p.]. Available from:
  86. Widder KJ, Morris RM, Poore GA, Howard DP, Senyei AE. Selective targeting of magnetic albumin microspheres containing low-dose doxorubicin: total remission in Yoshida sarcoma-bearing rats.1983;135-9.
  87. Lübbe AS, Bergemann C, Riess H, Schriever F, Reichardt P, Possinger K, et al. Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors.1996;4686-93.
  88. Alexiou C, Arnold W, Klein RJ, Parak FG, Hulin P, Bergemann C, et al. Locoregional cancer treatment with magnetic drug targeting.2000;6641-8.
  89. Goodwin SC, Bittner CA, Peterson CL, Wong G. Single-dose toxicity study of hepatic intra-arterial infusion of doxorubicin coupled to a novel magnetically targeted drug carrier.2001;177-83.
  90. Koda J, Venook A, Walser E. A multicenter, phase I/II trial of hepatic intra-arterial delivery of doxorubicin hydrochloride adsorbed to magnetic targeted carriers in patients with hepatocellular carcinoma.2002;S18.
  91. Wilson MW, Kerlan RK, Fidelman NA, Venook AP, LaBerge JM, Koda J, et al. Hepatocellular carcinoma: regional therapy with a magnetic targeted carrier bound to doxorubicin in a dual MR imaging/conventional angiography suite-initial experience with four patients.2004;287-93.
  92. ClinicalTrials.gov [Internet]. Bethesda (MD): National Institutes of Health (US); 1993 - . Safety and efficacy of doxorubicin adsorbed to magnetic beads Vs. IV doxorubicin in treating liver cancer [cited 2010 May 5]; [about 2 p.]. Available from:
  93. Kamensek U, Sersa G. Targeted gene therapy in radiotherapy.2008;115-35.
  94. Cemazar M, Jarm T, Sersa G. Cancer electrogene therapy with interleukin-12.2010;300-11.
  95. Krötz F, Sohn HY, Gloe T, Plank C, Pohl U. Magnetofection potentiates gene delivery to cultured endothelial cells.2003;425-34.
  96. Krötz F, de Wit C, Sohn HY, Zahler S, Gloe T, Pohl U, et al. Magnetofection-a highly efficient tool for antisense oligonucleotide delivery in vitro and in vivo.2003;700-10.
  97. Jahnke A, Hirschberger J, Fischer C, Brill T, Köstlin R, Plank C, et al. Intratumoral gene delivery of feIL-2, feIFN-gamma and feGM-CSF using magnetofection as a neoadjuvant treatment option for feline fibrosarcomas: a phase-I study.2007;599-606.
  98. Hüttinger C, Hirschberger J, Jahnke A, Köstlin R, Brill T, Plank C, et al. Neoadjuvant gene delivery of feline granulocyte-macrophage colony-stimulating factor using magnetofection for the treatment of feline fibrosarcomas: a phase I trial.2008;655-67.
  99. Lu Y, Madu CO. Viral-based gene delivery and regulated gene expression for targeted cancer therapy.2010;19-35.
  100. Russ V, Wagner E. Cell and tissue targeting of nucleic acids for cancer gene therapy.2007;1047-57.
  101. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. Direct gene transfer into mouse muscle in vivo.1990;1465-8.
  102. Ardehali A, Fyfe A, Laks H, Drinkwater DC, Qiao JH, Lusis AJ. Direct gene transfer into donor hearts at the time of harvest.1995;716-20.
  103. Schwarz ER, Speakman MT, Patterson M, Hale SS, Isner JM, Kedes LH, et al. Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat-angiogenesis and angioma formation.2000;1323-30.
  104. Mueller C, Graessmann A, Graessmann M. Mapping of early SV40-specific functions by microinjection of different early viral DNA fragments.1978;579-85.
  105. Neumann E, Schaefer-Ridder M, Wang Y, Hofschneider PH. Gene transfer into mouse lyoma cells by electroporation in high electric fields.1982;841-5.
  106. Sanford JC, Klein TM, Wolf ED, Allen N. Delivery of substances into cells and tissues using a particle bombardment process.1987;27-37.
  107. Bao S, Thrall BD, Miller DL. Transfection of a reporter plasmid into cultured cells by sonoporation in vitro.1997;953-9.
  108. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA.1999;1258-66.
  109. McKnight T, Melechko A, Griffin G, Guillorn MA, Merkulov VI, Serna F, et al. Intracellular integration of synthetic nanostructures with viable cells for controlled biochemical manipulation.2003;551-6.
  110. Ohlfest JR, Freese AB, Largaespada DA. Nonviral vectors for cancer gene therapy: prospects for integrating vectors and combination therapies.2005;629-41.
  111. Morishita N, Nakagami H, Morishita R, Takeda S, Mishima F, Terazono B, et al. Magnetic nanoparticles with surface modification enhanced gene delivery of HVJ-E vector.2005;1121-6.
  112. Mah C, Zolotukhin I, Fraites T, Dobson J, Batich C, Byrne B. Microsphere-mediated delivery of recombinant AAV vectors in vitro and in vivo.2000;239S.
  113. Xenariou S, Griesenbach U, Ferrari S, Dean P, Scheule RK, Cheng SH, et al. Using magnetic forces to enhance non-viral gene transfer to airway epithelium in vivo.2006;1545-52.
  114. Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine.1995;7297-301.
  115. Pan X, Guan J, Yoo JW, Epstein AJ, Lee LJ, Lee RJ. Cationic lipid-coated magnetic nanoparticles associated with transferrin for gene delivery.2008;263-70.
  116. Xiang JJ, Nie XM, Tang JQ, Wang YJ, Li Z, Gan K, et al. In vitro gene transfection by magnetic iron oxide nanoparticles and magnetic field increases transfection efficiency.2004;71-4.
  117. Yang SY, Sun JS, Liu CH, Tsuang YH, Chen LT, Hong CY, et al. Ex vivo magnetofection with magnetic nanoparticles: a novel platform for nonviral tissue engineering.2008;195-204.
  118. Ino K, Kawasumi T, Ito A, Honda H. Plasmid DNA transfection using magnetite cationic liposomes for construction of multilayered gene-engineered cell sheet.2008;168-76.
  119. Kamau Chapman SW, Hassa PO, Koch-Schneidemann S, von Rechenberg B, Hofmann-Amtenbrink M, Steitz B, et al. Application of pulsed-magnetic field enhances non-viral gene delivery in primary cells from different origins.2008;1517-27.
  120. Chorny M, Polyak B, Alferiev IS, Walsh K, Friedman G, Levy RJ. Magnetically driven plasmid DNA delivery with biodegradable polymeric nanoparticles.2007;2510-9.
  121. Kamau SW, Hassa PO, Steitz B, Petri-Fink A, Hofmann H, Hofmann-Amtenbrink M, et al. Enhancement of the efficiency of non-viral gene delivery by application of pulsed magnetic field.2006;e40.
  122. McBain S, Griesenbach U, Xenariou S, Keramane A, Batich CD, Alton EWFW, et al. Magnetic nanoparticles as gene delivery agents: enhanced transfection in the presence of oscillating magnet arrays.2008;: 1-5.
  123. Maass G, Schweighoffer T, Berger M, Schmidt W, Herbst E, Zatloukal K, et al. Tumor vaccines: effects and fate of IL-2 transfected murine melanoma cells in vivo.1995;65-73.
  124. Schmidt W, Schweighoffer T, Herbst E, Maass G, Berger M, Schilcher F, et al. Cancer vaccines: the interleukin 2 dosage effect.1995;: 4711-4.
  125. Kircheis R, Küpcü Z, Wallner G, Wagner E. Cytokine gene-modified tumor cells for prophylactic and therapeutic vaccination: IL-2, IFN-gamma, or combination IL-2 + IFN-gamma.1998;95-103.
DOI: https://doi.org/10.2478/v10019-011-0001-z | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Language: English
Page range: 1 - 16
Published on: Jan 19, 2011
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2011 Sara Prijic, Gregor Sersa, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons License.